Utility of a monitoring strategy for human herpesviruses 6 and 7 viremia after liver transplantation: A randomized clinical trial

Transplantation

Volumn 99, Issue 1, 2015, Pages 106-113

  Fernández Ruiz, Mario ^a   Kumar, Deepali ^a   Husain, Shahid ^a   Lilly, Les ^a   Renner, Eberhard ^a   Mazzulli, Tony ^b   Moussa, George ^b   Humar, Atul ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CANADA; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DRUG DOSE INCREASE; EVENT FREE SURVIVAL; FEMALE; HEALTH IMPACT ASSESSMENT; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; INCIDENCE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT MONITORING; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT DURATION; VIREMIA; VIRUS INFECTION; VIRUS LOAD; VIRUS REACTIVATION; GENETICS; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PREDICTIVE VALUE; RISK; ROSEOLOVIRUS INFECTIONS; TIME; VIROLOGY;

ADULT; FEMALE; HERPESVIRUS 6, HUMAN; HERPESVIRUS 7, HUMAN; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; ODDS RATIO; ONTARIO; OPPORTUNISTIC INFECTIONS; PREDICTIVE VALUE OF TESTS; REAL-TIME POLYMERASE CHAIN REACTION; ROSEOLOVIRUS INFECTIONS; TIME FACTORS; VIRAL LOAD; VIREMIA;

EID: 84920262857     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000306     Document Type: Article

References (36)

1. Zerr DM. Human herpesvirus 6: a clinical update. Herpes 2006;13:20.
2. Black JB, Pellett PE. Human herpesvirus 7. Rev Med Virol 1999;9:245.
3. Flamand L, Komaroff AL, Arbuckle JH, et al. Review, part 1: human herpesvirus-6-basic biology, diagnostic testing, and antiviral efficacy. J Med Virol 2010;82:1560.
4. Razonable RR. Human herpesviruses 6, 7 and 8 in solid organ transplant recipients. Am J Transplant 2013;13(Suppl 3):67.
5. Dockrell DH, Paya CV. Human herpesvirus-6 and-7 in transplantation. Rev Med Virol 2001;11:23.
6. Flamand L, Gosselin J, Stefanescu I, et al. Immunosuppressive effect of human herpesvirus 6 on T-cell functions: suppression of interleukin-2 synthesis and cell proliferation. Blood 1995;85:1263.
7. Atedzoe BN, Ahmad A, Menezes J. Enhancement of natural killer cell cytotoxicity by the human herpesvirus-7 via IL-15 induction. J Immunol 1997;159:4966.
8. Humar A, Kumar D, Caliendo AM, et al. Clinical impact of human herpesvirus 6 infection after liver transplantation. Transplantation 2002;73:599.
9. DesJardin JA, Gibbons L, Cho E, et al. Human herpesvirus 6 reactivation is associated with cytomegalovirus infection and syndromes in kidney transplant recipients at risk for primary cytomegalovirus infection. J Infect Dis 1998;178:1783.
10. Rogers J, Rohal S, Carrigan DR, et al. Human herpesvirus-6 in liver transplant recipients: role in pathogenesis of fungal infections, neurologic complications, and outcome. Transplantation 2000;69:2566.
11. Humar A, Kumar D, Raboud J, et al. Interactions between cytomegalovirus, human herpesvirus-6, and the recurrence of hepatitis C after liver transplantation. Am J Transplant 2002;2:461.
12. Humar A, Asberg A, Kumar D, et al. An assessment of herpesvirus coinfections in patients with CMV disease: correlation with clinical and virologic outcomes. Am J Transplant 2009;9:374.
13. Baron C, Forconi C, Lebranchu Y. Revisiting the effects of CMV on longterm transplant outcome. Curr Opin Organ Transplant 2010;15:492.
14. Ward KN, Leong HN, Nacheva EP, et al. Human herpesvirus 6 chromosomal integration in immunocompetent patients results in high levels of viral DNA in blood, sera, and hair follicles. J Clin Microbiol 2006;44:1571.
15. Pellett PE, Ablashi DV, Ambros PF, et al. Chromosomally integrated human herpesvirus 6: questions and answers. Rev Med Virol 2012;22:144.
16. Dockrell DH, Mendez JC, Jones M, et al. Human herpesvirus 6 seronegativity before transplantation predicts the occurrence of fungal infection in liver transplant recipients. Transplantation 1999;67:399.
17. Härmä M, Höckerstedt K, Lyytikäinen O, et al. HHV-6 and HHV-7 antigenemia related to CMV infection after liver transplantation. J Med Virol 2006;78:800.
18. Burns WH, Sandford GR. Susceptibility of human herpesvirus 6 to antivirals in vitro. J Infect Dis 1990;162:634.
19. Yoshida M, Yamada M, Tsukazaki T, et al. Comparison of antiviral compounds against human herpesvirus 6 and 7. Antiviral Res 1998; 40:73.
20. Mookerjee BP, Vogelsang G. Human herpes virus-6 encephalitis after bone marrow transplantation: successful treatment with ganciclovir. Bone Marrow Transplant 1997;20:905.
21. Yoshida H, Matsunaga K, Ueda T, et al. Human herpesvirus 6 meningoencephalitis successfully treated with ganciclovir in a patient who underwent allogeneic bone marrow transplantation from an HLAidentical sibling. Int J Hematol 2002;75:421.
22. Razonable RR, Brown RA, Humar A, et al. Herpesvirus infections in solid organ transplant patients at high risk of primary cytomegalovirus disease. J Infect Dis 2005;192:1331.
23. Brennan DC, Storch GA, Singer GG, et al. The prevalence of human herpesvirus-7 in renal transplant recipients is unaffected by oral or intravenous ganciclovir. J Infect Dis. 2000;181:1557.
24. Abdel Massih RC, Razonable RR. Human herpesvirus 6 infections after liver transplantation. World J Gastroenterol 2009;15:2561.
25. Lautenschlager I, Härmä M, Höckerstedt K, et al. Human herpesvirus-6 infection is associated with adhesion molecule induction and lymphocyte infiltration in liver allografts. J Hepatol 2002;37:648.
26. Lautenschlager I,Höckerstedt K, Linnavuori K, et al.Human herpesvirus-6 infection after liver transplantation. Clin Infect Dis 1998;26:702.
27. Griffiths PD, Ait-Khaled M, Bearcroft CP, et al. Human herpesviruses 6 and 7 as potential pathogens after liver transplant: prospective comparison with the effect of cytomegalovirus. J Med Virol 1999;59:496.
28. Arena A, Liberto MC, Iannello D, et al. Altered cytokine production after human herpes virus type 6 infection. New Microbiol 1999;22:293.
29. Santoro F, Kennedy PE, Locatelli G, et al. CD46 is a cellular receptor for human herpesvirus 6. Cell 1999;99:817.
30. Tong CY, Bakran A,Williams H, et al. Association of human herpesvirus 7 with cytomegalovirus disease in renal transplant recipients. Transplantation 2000;70:213.
31. Peigo MF, Thomasini RL, Puglia AL, et al. Human herpesvirus-7 inBrazilian liver transplant recipients: a follow-up comparison betweenmolecular and immunological assays. Transpl Infect Dis 2009;11:497.
32. Humar A, Michaels M, AST ID Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006;6:262.
33. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813.
34. Garrido RS, Aguado JM, Diaz-Pedroche C, et al. A review of critical periods for opportunistic infection in the new transplantation era. Transplantation 2006;82:1457.
35. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November, 1997. Hematol J 2000;1:53.
36. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24:289.